<DOC>
	<DOCNO>NCT01082224</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , contrast-enhanced CT scan contrast-enhanced MRI , may help find liver cancer find far disease spread . PURPOSE : This clinical trial study contrast-enhanced CT scan contrast-enhanced MRI diagnose stag liver cancer patient chronic liver disease .</brief_summary>
	<brief_title>Contrast-Enhanced CT MRI Diagnosing Staging Liver Cancer Using UNOS Policy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare sensitivity multiphase contrast-enhanced CT scan multiphase contrast-enhanced MRI use non-specific contrast agent diagnose hepatocellular carcinoma ( HCC ) patient chronic liver disease . Secondary - To compare positive predictive value ( PPV ) CT scan MRI diagnose HCC . - To compare lesion-level sensitivity PPV CT scan MRI interpret radiologist respective transplant center . - To compare sensitivity specificity multiphase contrast-enhanced CT scan v MRI diagnose residual recurrent HCC local ablative therapy patient list liver transplant . - To determine accuracy imaging-based diagnosis stag HCC clinical practice use new Organ Procurement Transplantation Network ( OPTN ) liver-imaging criterion compare reference standard pathologic diagnosis stag time explantation . - To explore whether comparison sensitivity PPV affect stratify patient AFP level ( elevated v normal ) . ( Exploratory ) Tertiary - To assess sensitivity PPV MRI CT interpret participate site basis available information sequence compare sensitivity PPV two modality interpret use main study criterion . ( Exploratory ) OUTLINE : This multicenter study . Patients stratify accord AFP level ( elevated v normal ) . Patients undergo CT scan iodinate contrast agent MRI extracellular gadolinium contrast agent ( standard-of-care study-related ) baseline 90-day interval liver transplant wait list . After transplantation , explanted liver analyzed biomarkers study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Presence ≥ 1 focal liver lesion ( ) compatible image diagnosis stage II hepatocellular carcinoma ( HCC ) ( Organ Procurement Transplantation Network [ OPTN ] Class 5B liver lesion ) contrastenhanced CT scan and/or contrastenhanced MRI OR 2 3 focal liver lesion , &gt; 1 &lt; 3 cm diameter , compatible image diagnosis HCC contrastenhanced CT image and/or contrastenhanced MRI Imaging finding must within Milan criterion Listed regional OPTN/United Network Organ Sharing ( UNOS ) liver transplant wait list HCCexception MELD point Listed intent undergo either decease donor transplantation live donor adult liver transplantation No evidence follow : Extrahepatic tumor Unifocal tumor mass &gt; 5 cm diameter Multifocal tumor ≥ 4 number Multiple ( ≤ 3 ) HCC ≥ 1 tumor ≥ 3 cm diameter PATIENT CHARACTERISTICS : No renal failure , determine estimate GFR ( eGFR ) &lt; 30 mL/min No renal insufficiency , determine eGFR 3060 mL/min Not pregnant Negative pregnancy test Able comply breathe imagingrelated instruction result ability obtain diagnosticquality CT scan MRI study ( OPTN Class 0 ) None follow condition would make patient unsuitable undergo MRI extracellular gadoliniumbased contrast agent dominant hepatobiliary excretion : Claustrophobia ( unless alleviate sedative treatment ) Presence metallic object implant medical device body per institutional safety standard Sickle cell disease Weight great allowable MRI table None follow condition would make patient unsuitable undergo CT scan iodinate contrast agent : Iodinated contrast allergy Weight great allowable CT table No know allergylike reaction contrast medium ( iodinated extracellular gadolinium dominant hepatobiliary excretion ) moderate severe allergic reaction one allergen defined American College Radiology unwilling undergo pretreatment PRIOR CONCURRENT THERAPY : No local ablative therapy liver study enrollment No prior concurrent sorafenib ( comparable antiangiogenic therapy ) Patients plan undergo local ablative therapy transplant listing study enrollment eligible provide undergo CT scan MRI within 2860 day complete last ablative therapy session Patients plan receive transcatheter arterial chemoembolization ( TACE ) combination therapy TACE thermal ablation eligible provide complete entire treatment scheme per institutional standard care undergo CT scan MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>